344860 — Innogene Co Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesHighly SpeculativeMicro CapFalling Star

Annual income statement for Innogene Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Interim Report	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	—	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	5,644	7,181	9,385	9,139	10,101
Cost of Revenue
Gross Profit	4,125	5,367	7,324	6,787	7,329
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	5,898	6,210	6,986	7,652	8,875
Operating Profit	-254	971	2,399	1,488	1,226
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-349	801	2,436	1,545	1,706
Provision for Income Taxes
Net Income After Taxes	-412	790	2,258	1,339	1,396
Net Income Before Extraordinary Items
Net Income	-412	790	2,258	1,339	1,396
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-412	790	2,258	1,339	1,396
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-339	100	243	144	120
Dividends per Share